Đánh giá đáp ứng sinh học phân tử sau 3 tháng điều trị trên bệnh nhân bạch cầu mạn dòng tủy mới chẩn đoán

The aim of the present work was to undertake an assessment of early molecular response to imatinib in patients with chronic myeloid leukemia in blood transfusion and hematology hospital. Subjects and methods: Retrospective descriptive study of 63 newly diagnosed chronic myeloid leukemia patients in chronic phase at blood transfusion and hematology hospital from June 2020 to February 2021. Results: Median age is 40.94 (12-72). At 3 months, the number of patients with BCR/ABL ≤ 10% accounted for a high rate of 76.2% (48/63 patients), the number of patients with BCR/ABL > 10% accounted for 23.8% (15/63). The correlation between the IELTs scores and EMR is statistically significant. Conclusion: Chronic myeloid leukemia treated with imatinib 400 mg/day achieved an early biological molecular response after 3 months, accounting for over 50%. However, the number of patients who did not achieve EMR after 3 months of treatment was 23.8%. The problem that needs to be raised is to change the treatment strategy for the patient by using the next generation TKIs so that the patient achieves a better molecular biological response.